Research ArticleClinical Studies
Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
TAKURO OKADA, TAKASHI MATSUKI, CHIHIRO FUSHIMI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KUNIHIKO TOKASHIKI, TATSUYA ITO, TATSUO MASUBUCHI, YUICHIRO TADA, KOUKI MIURA, KENJI HANYU, GO OMURA, HIDEKI TAKAHASHI, TAKU YAMASHITA, NOBUHIKO ORIDATE and KIYOAKI TSUKAHARA
Anticancer Research October 2022, 42 (10) 4907-4912; DOI: https://doi.org/10.21873/anticanres.15996
TAKURO OKADA
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;
TAKASHI MATSUKI
2Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan;
CHIHIRO FUSHIMI
3Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan;
ISAKU OKAMOTO
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;
HIROKI SATO
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;
TAKAHITO KONDO
4Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan;
KUNIHIKO TOKASHIKI
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;
TATSUYA ITO
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;
TATSUO MASUBUCHI
3Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan;
YUICHIRO TADA
3Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan;
KOUKI MIURA
3Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan;
KENJI HANYU
3Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan;
GO OMURA
5Department of Head and Neck Oncology, National Cancer Center Hospital, Tokyo, Japan;
HIDEKI TAKAHASHI
6Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, Yokohama, Japan
TAKU YAMASHITA
2Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan;
NOBUHIKO ORIDATE
6Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, Yokohama, Japan
KIYOAKI TSUKAHARA
1Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;

Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
patientACCESS
patientACCESS - Patients desiring access to articles
In this issue
Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
TAKURO OKADA, TAKASHI MATSUKI, CHIHIRO FUSHIMI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KUNIHIKO TOKASHIKI, TATSUYA ITO, TATSUO MASUBUCHI, YUICHIRO TADA, KOUKI MIURA, KENJI HANYU, GO OMURA, HIDEKI TAKAHASHI, TAKU YAMASHITA, NOBUHIKO ORIDATE, KIYOAKI TSUKAHARA
Anticancer Research Oct 2022, 42 (10) 4907-4912; DOI: 10.21873/anticanres.15996
Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
TAKURO OKADA, TAKASHI MATSUKI, CHIHIRO FUSHIMI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KUNIHIKO TOKASHIKI, TATSUYA ITO, TATSUO MASUBUCHI, YUICHIRO TADA, KOUKI MIURA, KENJI HANYU, GO OMURA, HIDEKI TAKAHASHI, TAKU YAMASHITA, NOBUHIKO ORIDATE, KIYOAKI TSUKAHARA
Anticancer Research Oct 2022, 42 (10) 4907-4912; DOI: 10.21873/anticanres.15996
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.